Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel.

Olaparib is the first poly(ADP-ribose) polymerase inhibitor approved as maintenance therapy of recurrent ovarian cancer (OC) patients with a BRCA mutation. To achieve the maximum clinical benefit, adherence to olaparib must be persistent. However, in clinical practice, this is challenged by the freq...

Descripción completa

Detalles Bibliográficos

Publicado en:	Supportive Care in Cancer Vol. 28; no. 5; pp. 2435 - 2443
Autores principales:	Lorusso, Domenica, Bologna, Alessandra, Cecere, Sabrina Chiara, De Matteis, Elisabetta, Scandurra, Giusy, Zamagni, Claudio, Arcangeli, Valentina, Artioli, Fabrizio, Bella, Mariangela, Blanco, Giusi, Cardalesi, Cinzia, Casartelli, Clelia, De Vivo, Rocco, Di Napoli, Marilena, Gisone, Emanuele Baldo, Lauria, Rossella, Lissoni, Alberto Andrea, Loizzi, Vera, Maccaroni, Elena, Mangili, Giorgia
Formato:	Journal Article
Publicado:	Springer Nature May2020
Acceso en línea:	Ver este registro en EBSCOhost